SQI in Can$7m private placement:
This article was originally published in Clinica
Toronto, Ontario-based SQI Diagnostics has announced a private placement offering of up to Can$7m ($6.6m) of units of the company. Each unit will consist of one share and one half of a share purchase warrant. The holder of a whole warrant will be entitled to acquire one share within two years after completion of the offering. Research Capital and Kinsdale Capital Markets have been appointed as agents of the transaction. SQI develops automated diagnostic systems for high-volume, multiple biomarker testing. Targeting the US$1.4bn autoimmune disease market, the company is expecting to launch its first products for rheumatoid arthritis and thrombosis in 2007.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.